🔗 Share this article

Given that America continues making historic adjustments to its vaccine guidelines, a particular individual has surfaced unexpectedly: Dr. Tracy Beth Høeg, an American of Danish descent sports physician and public health researcher who initially gained attention by casting doubt on Covid vaccines throughout the global health crisis and has concentrated on possible fatalities following COVID-19 immunization in her short time at the US Food and Drug Administration (FDA).

Proposed Overhauls to Childhood Immunization Program

Health officials were set to reveal major changes to the pediatric vaccine schedule in December, synchronizing the US with Denmark’s national calendar, according to reports – a major change that would place the US at odds with many the international standard with no evidence for public health gain. The planned update has been postponed until the next year.

In place of the top vaccines chief, Høeg is listed to present at the event. She was just designated acting director of the FDA’s drug evaluation center, the fifth person to run the office this calendar year.

A Shift at the FDA

This interim role might represent a tighter collaboration between the pharmaceutical and biologics divisions as Høeg and Prasad consolidate power at the agency – and it signals a greater focus upon rolling back already-approved immunizations at the FDA.

The new acting director has frequently advocated for halting certain childhood vaccine recommendations in the US so as to align more in line with Denmark's approach, a society with universal health coverage and a population about the population of the state of Wisconsin.

So far public appearances, she has persisted in emphasizing on vaccines – typically the responsibility of Prasad, head of the FDA’s vaccine center – rather than medication approval.

Doubts Over Background

The appointee has no obvious experience in pharmaceutical research, regulation or management, which has been typical for past directors of the biologics center. She has worked at the FDA as a key advisor to the agency head and CBER since spring.

“It seems she lacks to have the necessary background” for running the CDER, stated Jonathan Howard. “She has not conducted a randomized controlled trial. She lacks experience in leading a major agency. She lacks background in industry regulation.”

Past directors of the center would “grasp laws and regulations and the science of medication creation”, commented a former acting FDA commissioner. “Frankly, she lacks the type of experience that former directors who headed the center have had.”

CDER has an enormous workload at the FDA, Woodcock pointed out.

“Everybody just focuses on the innovative therapies, but the off-patent medication office authorizes numerous off-brand pharmaceuticals. There is also a biosimilars program, over-the-counter program and more, and each of these must be looked after,” Woodcock explained. “The thing you overlook, that is the part that I always told people is going to bite you.”

Additionally, a major management aspect to the position, which supervises in excess of 5,000 staff members. “It’s a massive administrative position, if you perform it correctly,” she said.

Official Statement and Controversial Initiatives

In response to questions about Høeg’s qualifications and whether this selection indicates greater collaboration among regulatory chiefs on immunizations, a spokesperson responded that the “inquiries are based on inaccurate presumptions”.

“Her resume is consistent with the duties of her job,” the spokesperson said, noting the period Dr. Høeg spent advising the agency head on “drug safety and approval science, including computational safety modeling and shot safety tracking”.

As acting director, Dr. Høeg takes over the agency head's recently launched expedited review system, a contentious one-day drug-approval program that reportedly troubled her former heads. “How are these medications being picked for this fast-track system? Who takes the decisions?” Howard said. “There’s a lot of lack of transparency occurring at the regulatory body right now.”

Broadly speaking, he said, “the FDA looks to be trending towards laxer regulations of most medications, with the exception of immunizations.”

Documented Past Work on Immunizations

Concerning immunizations, Høeg has a clearer, if concerning, track record, Howard have noted. She released a study using unverified public submissions to determine the frequency of myocarditis after COVID-19 immunization. She consulted for the state of Florida surgeon general Dr. Joseph Ladapo, who reportedly have altered data to indicate COVID-19 vaccinations are riskier than they are.

Part of her “desired changes” for the incoming federal leadership included altering regulations for novel immunizations and ending “unnecessary” vaccines, she stated after the election on a audio program. At the agency, Dr. Høeg has according to sources proposed excluding adolescent males from getting COVID-19 vaccines.

“She is an thorough ideologue who begins with her preconceived notions and tailors the evidence to accommodate the evidence in a highly disingenuous, fraudulent manner,” Dr. Howard stated.

Consolidating Power and a “Campaign of Retribution”

Høeg aligned with other skeptics, {like|